+1 862-686-2696
Featured Products
Primary Cells
Immortalized Cell Lines
Stem Cells
Tumor Cell Lines
Transfected Stable Cell Lines
Exosomes
MicroRNA Agomir/Antagomir
Cell Culture Media, Kits & Reagents
Explore Products
Cell
Cell
MicroRNA
MicroRNA
Test and Analysis
Test and Analysis
Transfected Stable Cell Lines

CD19/CD20 Double Knockout Raji Cell Line

  • For research use only

Cat No.

ABC-KH008Y
Product Type

Knockout Stable Cell Line
Cell Type

Lymphoblast-like
Species

Human
Host Cell

Raji
Source Organ

Peripheral Blood
Disease

Burkitt’s Lymphoma
Storage

Liquid Nitrogen

CD19/CD20 Double Knockout Raji Cell Line by AcceGen enables precise evaluation of B-cell depletion therapies and combination immunotherapy mechanisms.

Product Image
  • CD19/CD20 Double Knockout Raji Cell Line
Get a Quote
Home | Transfected Stable Cell Lines | CD19/CD20 Double Knockout Raji Cell Line

Description

The CD19/CD20 Double Knockout Raji Cell Line is a genetically engineered human Burkitt’s lymphoma model created by CRISPR/Cas9-mediated disruption of both CD19 and CD20 genes—two key B-cell surface markers critical for B-cell receptor signaling and therapeutic targeting. This double knockout results in complete loss of CD19/CD20 expression while preserving the suspension growth and spherical morphology typical of parental Raji cells. It provides a powerful platform for studying B-cell development, resistance mechanisms to CD19- and CD20-targeted immunotherapies, and evaluation of antibody-drug conjugates, bispecific antibodies, and CAR-T therapies. Knockout efficiency is validated by flow cytometry, genomic PCR, and Sanger sequencing. The cell line is maintained at low passage (<P20) for genetic stability and is rigorously tested to confirm it is free of HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.

Species

Human
Cat.No

ABC-KH008Y
Product Category

Transfected Stable Cell Lines
Size/Quantity

1 vial
Cell Type

Lymphoblast-like
Growth Mode

Suspension
Shipping Info

Dry Ice
Growth Conditions

37 ℃, 5% CO2
Source Organ

Peripheral Blood
Disease

Burkitt’s Lymphoma
Biosafety Level

1
Storage

Liquid Nitrogen
Product Type

Knockout Stable Cell Line
Host Cell

Raji
Gene Info

CD19 / CD20
Quality Control

All cells test negative for mycoplasma, bacteria, yeast, and fungi.

Application

  • This engineered Burkitt’s lymphoma model lacks both CD19 and CD20. The CD19/CD20 Double KnockoutRaji Cell Line is a specialized research tool for studying B-cell biology and immunotherapy development. By eliminating CD19 and CD20 expression, it enables investigations into resistance mechanisms, alternative targeting strategies, and novel therapeutic approaches for B-cell malignancies. This cell line is particularly valuable for evaluating CAR-T therapies, antibody-drug conjugates, and bispecific antibodies in a controlled setting. Its double-knockout feature helps researchers assess off-target effects and explore new biomarkers, making it a versatile model for drug discovery and translational studies in hematologic cancers.

  • Online Inquiry
  • Product Reviews

Inquiring CD19/CD20 Double Knockout Raji Cell Line

We know how valuable your research is to you, but are you wondering what you can expect to pay for quick accurate results every time? Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.
High Viability
To succeed in cell culture
Precision and Reliability
To support a consistent result
Customization Options
Tailed to your research

Tags

Let's Advance Life Science Research Together

Contact Us
AcceGen Scroll Top Button